Home » Topics » BioWorld Science

BioWorld Science
RSS

Plasmin/kallikrein inhibitors from Hisamitsu

May 3, 1996

Hepagene preliminary phase III results look positive

May 3, 1996

Somatix hepatitis therapy receives patent coverage

May 3, 1996

Kureha's new agent for renal disorders

May 3, 1996

Fujisawa synthesizes novel beta3-agonist

May 3, 1996

Reteplase multiple boluses claimed for thromboembolic conditions

May 3, 1996

PS-028: Fibrinogen antagonist from Taisho

May 3, 1996

Fuji Pharm. reports new antiplatelet agent

May 3, 1996

Servier develops S-18149 as putative venotropic agent

May 3, 1996

CPC-111 enters phase II for angioplasty indication

May 3, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Nov. 8, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for November 8, 2024.
Sales balloon for GLP-1 drugs from Novo Nordisk, Eli Lilly
BioWorld
Nearly $3.8 billion was earned by Novo Nordisk A/S and Eli Lilly and Co. in the third quarter for their glucagon-like peptide-1 (GLP-1) drugs to treat obesity....
Regulatory actions for Oct. 31, 2024
BioWorld
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Capsida, Electra,...
Australia reimburses Vazkepa a decade after US approval
BioWorld
For the first time, Australians have access to CSL Inc.’s Vazkepa (icosapent ethyl/Vascepa) for managing cardiovascular disease more than a decade after the drug...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.